Vivani Medical reports 82% sham-adjusted liver fat reduction with GLP-1 implant

Vivani Medical, Inc.

Sham-implant adjusted liver fat reduction of 82% in obese mouse model from single administration with twice-yearly dosing.
Previously reported 20% sham-implant adjusted weight loss, comparable to semaglutide arm.
Clinical development for NPM-115 program (exenatide implant) in overweight/obese patients on track for Q4 2024 start in Australia.
LIBERATE-1 first-in-human study expected to start Q4 2024 with data in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.